Guildford-based Ergomed, a company focused on providing specialised services to the global pharmaceutical industry, has announced its unaudited interim results for the six months ended 30 June 2021.
Key financial highlights include: total revenue of 38.8% over H1 2020 has gone up to £56.0 million (up 48.1% in constant currency), with adjusted EBITDA at £12.1 million, up 33% (H1 2020: £9.1 million). Furthermore, basic adjusted earnings per share of 16.8p have gone up 48.7% (H1 2020: 11.3p) and the net cash of £24.6 million has gone up 74.5% (30 June 2020: £14.1 million).
Some of the operational highlights are: net new sales awards have gone up 50.8% and North America revenues have gone up 70.8% to £35.5 million.
About Ergomed plc
Guildford-based Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance, and medical information.
Bristol engineering design consultants Hydrock has been acquired by Stantec. Hydrock has over 950 employees…
Plans from waterside developers Peel Waters to build a new business campus at Chatham Docks…
Europa Road has signed a contract with DPD Netherlands to run new daily line hauls…
Pure Human Resources, an HR, recruitment and training consultancy based in North Baddesley, Hampshire, is…
The Science Based Targets initiative (SBTi) has approved the near-team emissions reduction targets of medical…
Bagshot-based real estate investor and developer Sixpenny Group has acquired a 45,000 sq ft residential-led…